<DOC>
	<DOCNO>NCT02272777</DOCNO>
	<brief_summary>The extension study follow core study CAMN107ECN02 , open-label , two arm study . All patient enrol extension study able benefit treatment give CAMN107ECN02 per investigator 's evaluation . Therefore , extension study patient continue treatment drug ( imatinib nilotinib ) take end CAMN107ECN02 . Treatment arm CAMN107ECN02 retain . As long get EC approval agreement investigator , select site CAMN107ECN02 apply extension study . Patients enrol eligibility evaluation . During study , follow-up visit frequency 6 month require refer core study recommendation Chinese CML guideline . No data collection plan include extension study except safety data . Investigator ask report AE , SAE pregnancy order ensure compliance pharmacovigilance requirement . AE &amp; SAE information record CRF include clinical database . In addition , SAE pregnancy report Novartis safety database . The extension study start first patient last dose date CAMN107ECN02 end time nilotinib first line treatment commercially available China .</brief_summary>
	<brief_title>A Study Imatinib Nilotinib Patients With Chronic Myelogenous Leukemia Chronic Phase</brief_title>
	<detailed_description>The extension study follow core study CAMN107ECN02 , open-label , two arm study . All patient enrol extension study able benefit treatment give CAMN107ECN02 per investigator 's evaluation . Therefore , extension study patient continue treatment drug ( imatinib nilotinib ) take end CAMN107ECN02 . Treatment arm CAMN107ECN02 retain . As long get EC approval agreement investigator , select site CAMN107ECN02 apply extension study . Patients enrol eligibility evaluation . During study , follow-up visit frequency 6 month require refer core study recommendation Chinese CML guideline . No data collection plan include extension study except safety data . Investigator ask report AE , SAE pregnancy order ensure compliance pharmacovigilance requirement . AE &amp; SAE information record CRF include clinical database . In addition , SAE pregnancy report Novartis safety database . The extension study start first patient last dose date CAMN107ECN02 end time nilotinib first line treatment commercially available China . The patient continue derive benefit study treatment he/she take CAMN107ECN02 , opinion investigator , end core study enrol extension study . The investigator designee must ensure patient meet following inclusion none exclusion criterion offer treatment study . Up 230 patient enrol . Inclusion criteria： Patients eligible inclusion extension phase meet follow criterion : 1 . Patient currently treatment core study CAMN107ECN02 2 . Patient continue derive benefit risk study treatment he/she take CAMN107ECN02 , opinion investigator end study 3 . Written informed consent must obtain prior enrol extension study Exclusion criteria： Patients eligible extension phase must meet following criterion : 1 . Progression CML-AP BC 2 . Patient whose treatment assign CAMN107ECN02 appropriate longer , per investigator 's assessment . 3 . History non-compliance medical regimen , patient consider potentially unreliable and/or cooperative . 4 . Women ( ) pregnant ( b ) woman child-bearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose least 14 day last dose study medication . Highly effective contraception method include : - Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , post-ovulation method ) withdrawal acceptable method contraception - Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment - Male sterilization ( least 6 month prior screen ) . For female subject study vasectomized male partner sole partner subject . - Combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository In case use oral contraception woman stable pill minimum 3 month take study treatment . Investigational reference therapy：Nilotinib ( 300mg BID，400mg QD ) imatinib（recommended 600mg QD，400mg QD 300mg QD）</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion Criteria Patients eligible inclusion extension phase meet follow criterion : 1 . Patient currently treatment core study CAMN107ECN02 2 . Patient continue derive benefit risk study treatment he/she take CAMN107ECN02 , opinion investigator end study 3 . Written informed consent must obtain prior enrol extension study . Patients eligible extension phase must meet following criterion : 1 . Progression CMLAP BC 2 . Patient whose treatment assign CAMN107ECN02 appropriate longer , per investigator 's assessment . 3 . History noncompliance medical regimen , patient consider potentially unreliable and/or cooperative . 4 . Women ( ) pregnant ( b ) woman childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose least 14 day last dose study medication . Highly effective contraception method include : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment Male sterilization ( least 6 month prior screen ) . For female subject study vasectomized male partner sole partner subject . Combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository In case use oral contraception woman stable pill minimum 3 month take study treatment . Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week ago . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelogenous</keyword>
	<keyword>Chronic</keyword>
	<keyword>BCR-ABL Positive</keyword>
</DOC>